Show simple item record

dc.contributor.authorSafdari, Y
dc.contributor.authorKhalili, M
dc.contributor.authorEbrahimzadeh, MA
dc.contributor.authorYazdani, Y
dc.contributor.authorFarajnia, S
dc.date.accessioned2018-08-26T07:43:57Z
dc.date.available2018-08-26T07:43:57Z
dc.date.issued2015
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/48097
dc.description.abstractEpidermal growth factor receptor (EGFR) plays a critical role in the initiation and progression of a variety of human cancers, including breast cancer. An important signaling pathway downstream of EGFR is the PI3K/AKt pathway, which regulates cellular processes as diverse as cell growth, survival, proliferation and migration. Deregulated activity of this pathway may lead to uncontrolled cell growth, survival, migration and invasion, contributing to tumor formation. In this review, we evaluate natural compounds that, in vitro (breast cancer cell lines) and/or in vivo (animal model, clinical) studies, suppress breast cancer cells or tumors mainly by suppressing the PI3K/AKT signaling pathway. The effect of these compounds on cell cycle arrest, inhibition of cell migration and invasion, tumor angiogenesis and metastasis in breast cancer are discussed. (C) 2014 Elsevier Ltd. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofPHARMACOLOGICAL RESEARCH
dc.subjectBreast cancer
dc.subjectNatural inhibitors
dc.subjectPI3K
dc.subjectAKT
dc.titleNatural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action
dc.typeReview
dc.citation.volume93
dc.citation.spage1
dc.citation.epage10
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1016/j.phrs.2014.12.004


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record